Literature DB >> 29539391

Binding Modes of Phthalocyanines to Amyloid β Peptide and Their Effects on Amyloid Fibril Formation.

Ariel A Valiente-Gabioud1, Dietmar Riedel2, Tiago F Outeiro3, Mauricio A Menacho-Márquez1, Christian Griesinger4, Claudio O Fernández5.   

Abstract

The inherent tendency of proteins to convert from their native states into amyloid aggregates is associated with a range of human disorders, including Alzheimer's and Parkinson's diseases. In that sense, the use of small molecules as probes for the structural and toxic mechanism related to amyloid aggregation has become an active area of research. Compared with other compounds, the structural and molecular basis behind the inhibitory interaction of phthalocyanine tetrasulfonate (PcTS) with proteins such as αS and tau has been well established, contributing to a better understanding of the amyloid aggregation process in these proteins. We present here the structural characterization of the binding of PcTS and its Cu(II) and Zn(II)-loaded forms to the amyloid β-peptide (Aβ) and the impact of these interactions on the peptide amyloid fibril assembly. Elucidation of the PcTS binding modes to Aβ40 revealed the involvement of specific aromatic and hydrophobic interactions in the formation of the Aβ40-PcTS complex, ascribed to a binding mode in which the planarity and hydrophobicity of the aromatic ring system in the phthalocyanine act as main structural determinants for the interaction. Our results demonstrated that formation of the Aβ40-PcTS complex does not interfere with the progression of the peptide toward the formation of amyloid fibrils. On the other hand, conjugation of Zn(II) but not Cu(II) at the center of the PcTS macrocyclic ring modified substantially the binding profile of this phthalocyanine to Aβ40 and became crucial to reverse the effects of metal-free PcTS on the fibril assembly of the peptide. Overall, our results provide a firm basis to understand the structural rules directing phthalocyanine-protein interactions and their implications on the amyloid fibril assembly of the target proteins; in particular, our results contradict the hypothesis that PcTS might have similar mechanisms of action in slowing the formation of a variety of pathological aggregates.
Copyright © 2018 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29539391      PMCID: PMC5883547          DOI: 10.1016/j.bpj.2018.01.003

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  63 in total

Review 1.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

Review 2.  Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.

Authors:  Sergey O Bachurin; Elena V Bovina; Aleksey A Ustyugov
Journal:  Med Res Rev       Date:  2017-01-13       Impact factor: 12.944

3.  The Alzheimer beta-peptide shows temperature-dependent transitions between left-handed 3-helix, beta-strand and random coil secondary structures.

Authors:  Jens Danielsson; Jüri Jarvet; Peter Damberg; Astrid Gräslund
Journal:  FEBS J       Date:  2005-08       Impact factor: 5.542

Review 4.  Aβ-amyloid and Tau Imaging in Dementia.

Authors:  Victor L Villemagne; Vincent Doré; Pierrick Bourgeat; Samantha C Burnham; Simon Laws; Olivier Salvado; Colin L Masters; Christopher C Rowe
Journal:  Semin Nucl Med       Date:  2016-10-13       Impact factor: 4.446

Review 5.  Probing the biology of Alzheimer's disease in mice.

Authors:  Karen H Ashe; Kathleen R Zahs
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

6.  Toward the discovery of effective polycyclic inhibitors of alpha-synuclein amyloid assembly.

Authors:  Gonzalo R Lamberto; Valentina Torres-Monserrat; Carlos W Bertoncini; Xavier Salvatella; Markus Zweckstetter; Christian Griesinger; Claudio O Fernández
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

7.  An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments.

Authors:  Y Fezoui; D M Hartley; J D Harper; R Khurana; D M Walsh; M M Condron; D J Selkoe; P T Lansbury; A L Fink; D B Teplow
Journal:  Amyloid       Date:  2000-09       Impact factor: 7.141

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

Review 9.  Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide.

Authors:  Peter Faller; Christelle Hureau
Journal:  Dalton Trans       Date:  2008-11-26       Impact factor: 4.390

10.  Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.

Authors:  Jens Wagner; Sybille Krauss; Song Shi; Sergey Ryazanov; Julia Steffen; Carolin Miklitz; Andrei Leonov; Alexander Kleinknecht; Bettina Göricke; Jochen H Weishaupt; Daniel Weckbecker; Anne M Reiner; Wolfgang Zinth; Johannes Levin; Dan Ehninger; Stefan Remy; Hans A Kretzschmar; Christian Griesinger; Armin Giese; Martin Fuhrmann
Journal:  Acta Neuropathol       Date:  2015-10-06       Impact factor: 17.088

View more
  2 in total

1.  Aromaticity at position 39 in α-synuclein: A modulator of amyloid fibril assembly and membrane-bound conformations.

Authors:  Fiamma A Buratti; Nicola Boeffinger; Hugo A Garro; Jesica S Flores; Francisco J Hita; Phelippe do Carmo Gonçalves; Federico Dos Reis Copello; Leonardo Lizarraga; Giulia Rossetti; Paolo Carloni; Markus Zweckstetter; Tiago F Outeiro; Stefan Eimer; Christian Griesinger; Claudio O Fernández
Journal:  Protein Sci       Date:  2022-07       Impact factor: 6.993

2.  Modification of insulin amyloid aggregation by Zr phthalocyanines functionalized with dehydroacetic acid derivatives.

Authors:  Svitlana Chernii; Yuriy Gerasymchuk; Mykhaylo Losytskyy; Damian Szymański; Iryna Tretyakova; Anna Łukowiak; Vasyl Pekhnyo; Sergiy Yarmoluk; Viktor Chernii; Vladyslava Kovalska
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.